Omead Ostadan Resigns as President of Seer, Inc. and from Its Board of Directors
August 26, 2022 at 04:06 pm EDT
Share
On August 25, 2022, Omead Ostadan resigned from his position as President of Seer, Inc. (the Company) and from its Board of Directors (the Board) for personal reasons, each effective as of September 30, 2022. Effective as of September 30, 2022, the Board has reduced its size from ten members to nine members. In addition, on August 26, 2022, the Board appointed Omid Farokhzad, M.D. to the office of President of the Company, in addition to his current positions as Chief Executive Officer and Chair of the Board, effective as of Mr. Ostadan's resignation.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.